Agilent Technologies, Inc. (NYSE:A) Given Consensus Rating of “Moderate Buy” by Brokerages

Agilent Technologies, Inc. (NYSE:A) has received a consensus recommendation of “Moderate Buy” from the nineteen analysts that are covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $159.3529.

Several equities analysts have recently issued reports on A shares. Jefferies Financial Group assumed coverage on shares of Agilent Technologies in a research note on Thursday, July 9th. They set a “hold” rating and a $135.00 price target for the company. TD Cowen increased their price target on Agilent Technologies from $147.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Barclays lifted their price objective on Agilent Technologies from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Piper Sandler initiated coverage on shares of Agilent Technologies in a report on Thursday, June 11th. They set a “neutral” rating and a $150.00 price target for the company. Finally, Robert W. Baird upped their price objective on shares of Agilent Technologies from $155.00 to $156.00 and gave the company an “outperform” rating in a research note on Tuesday, May 26th.

Agilent Technologies Stock Performance

NYSE:A opened at $131.34 on Monday. The stock’s 50-day moving average is $127.49 and its 200-day moving average is $125.54. Agilent Technologies has a 1-year low of $108.35 and a 1-year high of $160.27. The company has a current ratio of 2.10, a quick ratio of 1.62 and a debt-to-equity ratio of 0.43. The stock has a market cap of $37.09 billion, a P/E ratio of 26.37, a price-to-earnings-growth ratio of 2.34 and a beta of 1.25.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, May 27th. The medical research company reported $1.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.41 by $0.08. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. The business had revenue of $1.83 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same quarter last year, the business earned $1.31 EPS. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. Equities research analysts anticipate that Agilent Technologies will post 6 earnings per share for the current year.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 22nd. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.255 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $1.02 dividend on an annualized basis and a yield of 0.8%. Agilent Technologies’s dividend payout ratio is 20.48%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in A. Fiduciary Trust Co grew its holdings in Agilent Technologies by 1.6% during the third quarter. Fiduciary Trust Co now owns 4,931 shares of the medical research company’s stock worth $633,000 after acquiring an additional 77 shares during the period. NorthCrest Asset Manangement LLC lifted its holdings in Agilent Technologies by 1.6% in the fourth quarter. NorthCrest Asset Manangement LLC now owns 5,082 shares of the medical research company’s stock valued at $726,000 after acquiring an additional 79 shares during the period. Freestone Capital Holdings LLC boosted its position in shares of Agilent Technologies by 2.0% during the 4th quarter. Freestone Capital Holdings LLC now owns 4,218 shares of the medical research company’s stock worth $574,000 after purchasing an additional 84 shares in the last quarter. Sapient Capital LLC boosted its position in shares of Agilent Technologies by 4.2% during the 1st quarter. Sapient Capital LLC now owns 2,105 shares of the medical research company’s stock worth $240,000 after purchasing an additional 85 shares in the last quarter. Finally, Grove Bank & Trust grew its stake in shares of Agilent Technologies by 5.5% during the 4th quarter. Grove Bank & Trust now owns 1,758 shares of the medical research company’s stock worth $239,000 after purchasing an additional 92 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.